Cardiac injury in COVID-19 is primarily driven by microthrombi with a unique composition, suggesting a potential role for tailored antithrombotic strategies.
Microthrombi with distinct composition may inform tailored antithrombotics for COVID-19 cardiac injury; extends pathological mechanisms beyond STEMI and non-COVID emboli.
The most common pathological cause of myocyte necrosis was microthrombi. Microthrombi were different in composition from intramyocardial thromboemboli from COVID-19-negative subjects and from coronary thrombi retrieved from COVID-19-positive and -negative patients with ST-segment-elevation myocardial infarction. Tailored antithrombotic strategies may be useful to counteract the cardiac effects of COVID-19 infection.
No takes yet. Share an insight, caveat, or question.
Pellegrini et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: